Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine Treadaway

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Medical Clinics of North America|March 11, 2009
Multiple sclerosisArdith M Courtney, Katherine Treadaway, Gina Remington, et al.
International Journal of MS Care|January 24, 2014
Facilitating medication adherence in patients with multiple sclerosisGina Remington, Yolanda Rodriguez, Diana Logan, et al.
Nature Clinical Practice. Urology|February 10, 2009
Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and managementSophie G Fletcher, Wanda Castro-Borrero, Gina Remington, et al.
Neurologic Clinics|July 23, 2016
Neurotherapeutic Strategies for Multiple SclerosisTeresa C Frohman, Shin C Beh, Eric J Kildebeck, et al.
Annals of Clinical and Translational Neurology|September 5, 2015
Aquatic training in MS: neurotherapeutic impact upon quality of lifeAshley N Frohman, Darin T Okuda, Shin Beh, et al.
Therapeutic Advances in Neurological Disorders|December 25, 2010
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS)Gina M Remington, Katherine Treadaway, Teresa Frohman, et al.
Therapeutic Advances in Neurological Disorders|June 23, 2011
Symptomatic therapy in multiple sclerosisTeresa C Frohman, Wanda Castro, Anjali Shah, et al.
Journal of Neurology|May 16, 2009
Factors that influence adherence with disease-modifying therapy in MSKatherine Treadaway, Gary Cutter, Amber Salter, et al.
Therapeutic Advances in Neurological Disorders|December 25, 2010
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosisElliot M Frohman, Gary Cutter, Gina Remington, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Medical Clinics of North America|March 11, 2009
Multiple sclerosisArdith M Courtney, Katherine Treadaway, Gina Remington, et al.
International Journal of MS Care|January 24, 2014
Facilitating medication adherence in patients with multiple sclerosisGina Remington, Yolanda Rodriguez, Diana Logan, et al.
Nature Clinical Practice. Urology|February 10, 2009
Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and managementSophie G Fletcher, Wanda Castro-Borrero, Gina Remington, et al.
Neurologic Clinics|July 23, 2016
Neurotherapeutic Strategies for Multiple SclerosisTeresa C Frohman, Shin C Beh, Eric J Kildebeck, et al.
Annals of Clinical and Translational Neurology|September 5, 2015
Aquatic training in MS: neurotherapeutic impact upon quality of lifeAshley N Frohman, Darin T Okuda, Shin Beh, et al.
Therapeutic Advances in Neurological Disorders|December 25, 2010
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS)Gina M Remington, Katherine Treadaway, Teresa Frohman, et al.
Therapeutic Advances in Neurological Disorders|June 23, 2011
Symptomatic therapy in multiple sclerosisTeresa C Frohman, Wanda Castro, Anjali Shah, et al.
Journal of Neurology|May 16, 2009
Factors that influence adherence with disease-modifying therapy in MSKatherine Treadaway, Gary Cutter, Amber Salter, et al.
Therapeutic Advances in Neurological Disorders|December 25, 2010
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosisElliot M Frohman, Gary Cutter, Gina Remington, et al.
Pageof 1